Of particular interest is the use of the combination of liposomal anthracyclines plus trastuzumab in patients with early and HER2-overexpressing breast cancer, as this is probably the subgroup that would benefit most from a treatment with anthracyclines. This evidence concerns the gene ERBB2 and breast carcinoma.